Georgetown, Canada Clinical Trials

A listing of Georgetown, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

cardiovascular disease
body mass index
overweight or obesity
Novo Nordisk Investigational Site
 (7.7 away) Contact site
  • 7712 views
  • 18 Jul, 2021
  • +1164 other locations
Study to Evaluate the Efficacy Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

nocturia
benign prostatic hypertrophy
alpha blocker
vibegron
cancer
Practice Dr Jonathan Giddens
 (9.0 away) Contact site
  • 959 views
  • 15 Jul, 2021
  • +170 other locations
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

hepatic fibrosis
liver disease
mri-pdff
fibrosis
ballooning degeneration
LMC/ Manna Research - Brampton
 (9.0 away) Contact site
  • 167 views
  • 17 Jul, 2021
  • +229 other locations
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.

angiography
macular degeneration
fluorescein angiography
vascular endothelial growth factor
brolucizumab
Novartis Investigative Site
 (8.0 away) Contact site
  • 30 views
  • 21 Jul, 2021
  • +134 other locations